{"id":62725,"date":"2026-04-09T20:19:29","date_gmt":"2026-04-09T12:19:29","guid":{"rendered":"https:\/\/flcube.com\/?p=62725"},"modified":"2026-04-09T20:19:30","modified_gmt":"2026-04-09T12:19:30","slug":"grand-pharma-partners-with-hku-on-anti-infective-drug-discovery-exclusive-license-deal-targets-novel-antibacterial-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62725","title":{"rendered":"Grand Pharma Partners with HKU on Anti\u2011Infective Drug Discovery \u2013 Exclusive License Deal Targets Novel Antibacterial Therapies"},"content":{"rendered":"\n<p><strong>Grand Pharmaceutical Group Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/0512:HKG\">HKG:\u202f0512<\/a>) announced a <strong>strategic partnership<\/strong> with <strong>The University of Hong Kong (HKU)<\/strong> and its wholly\u2011owned technology transfer arm, <strong>University of Hong Kong Versitech Limited<\/strong>, to accelerate innovation in <strong>anti\u2011infective drug discovery<\/strong> and commercialization of academic research.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure\">Partnership Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Grand Pharma (HKG:\u202f0512) + HKU \/ Versitech<\/td><\/tr><tr><td><strong>Scope<\/strong><\/td><td>Academic research, resource sharing, talent development, product development<\/td><\/tr><tr><td><strong>Initial Focus<\/strong><\/td><td>Innovative antibacterial drugs led by <strong>Prof. Li Xuecheng&#8217;s team<\/strong><\/td><\/tr><tr><td><strong>IP Arrangement<\/strong><\/td><td>Exclusive license to Grand Pharma for resultant intellectual property<\/td><\/tr><tr><td><strong>Grand Pharma Responsibilities<\/strong><\/td><td>R&amp;D, registration, commercialization<\/td><\/tr><tr><td><strong>HKU Role<\/strong><\/td><td>Early\u2011stage research, technology transfer<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-r-amp-d-strategy-amp-pipeline-focus\">R&amp;D Strategy &amp; Pipeline Focus<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lead Program:<\/strong> Novel antibacterial therapies with <strong>enhanced efficacy and safety profiles<\/strong><\/li>\n\n\n\n<li><strong>Target Indication:<\/strong> Unmet clinical needs in the antibacterial field, including drug\u2011resistant pathogens<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Next\u2011generation mechanisms addressing limitations of current antibiotic classes<\/li>\n\n\n\n<li><strong>Translation Model:<\/strong> &#8220;Lab\u2011to\u2011Market&#8221; pathway enabling rapid industrialization of HKU&#8217;s cutting\u2011edge research<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Academic\u2011Industry Synergy<\/strong><\/td><td>Access to HKU&#8217;s foundational research capabilities + Grand Pharma&#8217;s clinical development expertise<\/td><\/tr><tr><td><strong>IP Control<\/strong><\/td><td>Exclusive license ensures competitive moat and full commercial rights<\/td><\/tr><tr><td><strong>Talent Pipeline<\/strong><\/td><td>Joint development of R&amp;D workforce through structured collaboration<\/td><\/tr><tr><td><strong>Market Positioning<\/strong><\/td><td>Strengthens Grand Pharma&#8217;s anti\u2011infective portfolio amid rising global AMR threat<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global AMR Crisis:<\/strong> Antimicrobial resistance drives <strong>US$4\u202ftrillion<\/strong> in projected annual economic impact by 2050; novel antibacterial mechanisms command premium valuations and accelerated regulatory pathways.<\/li>\n\n\n\n<li><strong>China Innovation Push:<\/strong> Government policies incentivize academic\u2011industry partnerships; HKU&#8217;s research output ranks among Asia&#8217;s top institutions for biomedical sciences.<\/li>\n\n\n\n<li><strong>Portfolio Expansion:<\/strong> Deal complements Grand Pharma&#8217;s existing therapeutics focus, diversifying revenue streams beyond current commercialized products.<\/li>\n\n\n\n<li><strong>Milestone Timeline:<\/strong> Lead candidate expected to enter <strong>pre\u2011clinical development within 18\u201324\u202fmonths<\/strong>, with potential IND filing by 2028.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding partnership outcomes, pipeline progression, and commercial expectations. Actual results may differ due to risks including research failures, regulatory hurdles, IP challenges, and competitive dynamics in the anti\u2011infective market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Grand Pharmaceutical Group Co., Ltd. (HKG:\u202f0512) announced a strategic partnership with The University of Hong&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[],"class_list":["post-62725","post","type-post","status-publish","format-standard","hentry","category-company","category-deals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Grand Pharma Partners with HKU on Anti\u2011Infective Drug Discovery \u2013 Exclusive License Deal Targets Novel Antibacterial Therapies - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Grand Pharmaceutical Group Co., Ltd. (HKG:\u202f0512) announced a strategic partnership with The University of Hong Kong (HKU) and its wholly\u2011owned technology transfer arm, University of Hong Kong Versitech Limited, to accelerate innovation in anti\u2011infective drug discovery and commercialization of academic research.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62725\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Grand Pharma Partners with HKU on Anti\u2011Infective Drug Discovery \u2013 Exclusive License Deal Targets Novel Antibacterial Therapies\" \/>\n<meta property=\"og:description\" content=\"Grand Pharmaceutical Group Co., Ltd. (HKG:\u202f0512) announced a strategic partnership with The University of Hong Kong (HKU) and its wholly\u2011owned technology transfer arm, University of Hong Kong Versitech Limited, to accelerate innovation in anti\u2011infective drug discovery and commercialization of academic research.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62725\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-09T12:19:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-09T12:19:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62725#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62725\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Grand Pharma Partners with HKU on Anti\u2011Infective Drug Discovery \u2013 Exclusive License Deal Targets Novel Antibacterial Therapies\",\"datePublished\":\"2026-04-09T12:19:29+00:00\",\"dateModified\":\"2026-04-09T12:19:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62725\"},\"wordCount\":357,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62725#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62725\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62725\",\"name\":\"Grand Pharma Partners with HKU on Anti\u2011Infective Drug Discovery \u2013 Exclusive License Deal Targets Novel Antibacterial Therapies - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-09T12:19:29+00:00\",\"dateModified\":\"2026-04-09T12:19:30+00:00\",\"description\":\"Grand Pharmaceutical Group Co., Ltd. (HKG:\u202f0512) announced a strategic partnership with The University of Hong Kong (HKU) and its wholly\u2011owned technology transfer arm, University of Hong Kong Versitech Limited, to accelerate innovation in anti\u2011infective drug discovery and commercialization of academic research.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62725#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62725\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62725#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Grand Pharma Partners with HKU on Anti\u2011Infective Drug Discovery \u2013 Exclusive License Deal Targets Novel Antibacterial Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Grand Pharma Partners with HKU on Anti\u2011Infective Drug Discovery \u2013 Exclusive License Deal Targets Novel Antibacterial Therapies - Insight, China&#039;s Pharmaceutical Industry","description":"Grand Pharmaceutical Group Co., Ltd. (HKG:\u202f0512) announced a strategic partnership with The University of Hong Kong (HKU) and its wholly\u2011owned technology transfer arm, University of Hong Kong Versitech Limited, to accelerate innovation in anti\u2011infective drug discovery and commercialization of academic research.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62725","og_locale":"en_US","og_type":"article","og_title":"Grand Pharma Partners with HKU on Anti\u2011Infective Drug Discovery \u2013 Exclusive License Deal Targets Novel Antibacterial Therapies","og_description":"Grand Pharmaceutical Group Co., Ltd. (HKG:\u202f0512) announced a strategic partnership with The University of Hong Kong (HKU) and its wholly\u2011owned technology transfer arm, University of Hong Kong Versitech Limited, to accelerate innovation in anti\u2011infective drug discovery and commercialization of academic research.","og_url":"https:\/\/flcube.com\/?p=62725","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-09T12:19:29+00:00","article_modified_time":"2026-04-09T12:19:30+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62725#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62725"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Grand Pharma Partners with HKU on Anti\u2011Infective Drug Discovery \u2013 Exclusive License Deal Targets Novel Antibacterial Therapies","datePublished":"2026-04-09T12:19:29+00:00","dateModified":"2026-04-09T12:19:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62725"},"wordCount":357,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62725#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62725","url":"https:\/\/flcube.com\/?p=62725","name":"Grand Pharma Partners with HKU on Anti\u2011Infective Drug Discovery \u2013 Exclusive License Deal Targets Novel Antibacterial Therapies - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-09T12:19:29+00:00","dateModified":"2026-04-09T12:19:30+00:00","description":"Grand Pharmaceutical Group Co., Ltd. (HKG:\u202f0512) announced a strategic partnership with The University of Hong Kong (HKU) and its wholly\u2011owned technology transfer arm, University of Hong Kong Versitech Limited, to accelerate innovation in anti\u2011infective drug discovery and commercialization of academic research.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62725#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62725"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62725#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Grand Pharma Partners with HKU on Anti\u2011Infective Drug Discovery \u2013 Exclusive License Deal Targets Novel Antibacterial Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62725","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62725"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62725\/revisions"}],"predecessor-version":[{"id":62726,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62725\/revisions\/62726"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}